The Enara Bio® purpose
Shining a light on Dark Antigen® and T-cell biology to enable people to live free from the shadow of cancer. Our mission is to exploit previously uncharted genomic dark matter to develop cancer immunotherapies designed to provide lasting benefit for broad patient populations.
To achieve our mission, we have built an innovative technology platform called EDAPT®, which integrates bioinformatics, immunopeptidomics, target validation and immunology. The EDAPT platform enables us to discover a novel and differentiated class of cancer-specific targets from the genomic dark matter, which we call Dark Antigens. Our growing team has the depth of expertise and breadth of experience to advance this exciting area of immuno-oncology into novel therapeutics to benefit broad groups of cancer patients and their families.Read more about us
Who we are
We are a diverse, experienced, and rapidly growing team driven by a common purpose and united by our shared values. The culture we have developed enables each of us to make an impact and deliver on our vision.
- Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC) Licensed antigens are shared across major subsets of NSCLC and have confirmed presence on the surface of tumor cells, homogeneous expression within tumors, and strong immunogenicity
- Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium Event brings together leading academics, industry representatives and investors to share progress and discuss future directions in dark genome research and the development of novel therapeutics